USFDA inspects Cadila’s Moraiya facility

Drug firm Cadila Healthcare on Thursday said the US health regulator has inspected the company’s Moraiya plant and found it meeting the manufacturing norms. “The United States Food and Drug Administration (USFDA) inspected company’s Moraiya facility from February 6, 2017, to February 15, 2017. At the end of the inspection no observation (483) is issued,” Cadila Healthcare said. The FDA Form 483 notifies the company’s management of objectionable conditions. As per the US health regulator’s site “An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic Act and related Acts”.